A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response
Xiaoxiao Liu,Xiaobo Shi,Wei Guo,Yue Ke,Yuxing Li,Shupei Pan,Xiaona Li,Mei Liu,Mingzhu Liu,Yuchen Wang,Qinli Ruan,Hongbing Ma
DOI: https://doi.org/10.2147/IJGM.S327555
IF: 2.145
2021-09-18
International Journal of General Medicine
Abstract:Xiaoxiao Liu, 1 Xiaobo Shi, 1 Wei Guo, 1 Yue Ke, 1 Yuxing Li, 1 Shupei Pan, 1 Xiaona Li, 2 Mei Liu, 3 Mingzhu Liu, 4 Yuchen Wang, 1 Qinli Ruan, 1 Hongbing Ma 1 1 Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China; 2 Department of Dermatology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China; 3 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China; 4 Department of Gastroenterology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China Correspondence: Hongbing Ma Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China Tel +86 13991845066 Email Purpose: Ferroptosis and long non-coding RNA (lncRNA) expression signatures have been associated with the clinical progression and immune-contexture of different solid tumors. The study aimed to identify a prognostic signature of ferroptosis-related lncRNAs (falncRNAs) to forecast the immune scenery and immunotherapy response in esophageal cancer (EC). Patients and Methods: Gene expression profiles of EC were extracted from The Cancer Genome Atlas (TCGA) database, and ferroptosis-related genes were downloaded from the FerrDb database, which identified differentially expressed falncRNAs (DEfalncRNAs) via differential analysis. DEfalncRNA pairs associated with prognosis were identified by constructing a matrix, univariate and least absolute shrinkage and selection operator (LASSO) analysis. The prognostic signature was constructed by multivariate analysis. We appraised the forecasting capability of prognostic signature in survival, clinicopathological features, immune landscape, efficacy of immunotherapy, and drug sensitivity. The potential molecular mechanism of signature was investigated by gene set enrichment analysis (GSEA). Results: We obtained 18 DEfalncRNA pairs to define a novel prognostic signature that was determined on a discovery cohort of 158 tumor samples and 11 adjacent normal tissues from TCGA and internally validated, with the definition of high- vs low-risk groups based on 3 years overall survival. We demonstrated that the high- vs low-risk groups differed for clinical parameters and computationally predicted drug sensitivity and tumor immune contexture, with the high-risk group having worse survival, more aggressive disease (node involvement, metastasis), reduced drug sensitivity, higher tumor mutation load, and gene signatures of infiltration of pro-tumoral immune cell subsets. The GSEA results revealed that ferroptosis and immunoregulatory pathways were significantly enriched in the high-risk group. Conclusion: The prognostic signature based on falncRNAs has the potential to forecast the survival, immune scenery, efficacy of immunotherapy, and drug sensitivity of EC, which is helpful for clinical prediction and individualized treatment. Keywords: esophageal cancer, ferroptosis, lncRNA, immune, signature, prognosis Esophageal cancer (EC) is not only one of the most life-threatening gastrointestinal tumors but also one of the primary causes of cancer death worldwide. 1,2 In the cancer statistics of the United States in 2021, the number of new invasive EC cases is approximated to be 19,260 and 15,530 deaths from EC. 3 Almost half of EC patients worldwide are in China. 4 The morbidity and mortality of EC in Asia are expected to increase in the coming years. 5 By the high degree of malignancy, the 5-year relative survival rate of patients with EC is only 20%. 3 Prognostic risk factors for EC include smoking, alcohol consumption, obesity, age, tumor staging, and pathological type. 6–8 At present, surgery, chemotherapy, radiotherapy, immunotherapy, and molecular targeted therapy are the chief treatments for cancer in the world. 9–11 It has been found that ferroptosis is closely correlated with tumor cell growth inhibition. 12–15 Therefore, targeting ferroptosis has become a promising cancer therapeutic strategy. Ferroptosis is distinguished from the novel mode of programmed cell death of apoptosis, necrosis, and autophagy, which is chiefly characterized by cell death induced by iron-dependent phospholipid peroxide damage occurring within mitochondria. 14–16 Interferon-gamma (IFN-γ) released by CD8 + T cells activated by immunotherapy downregulated the expressi -Abstract Truncated-
medicine, general & internal